當(dāng)前位置：首頁(yè) SCI期刊 SCIE期刊醫(yī)學(xué) 中科院1區(qū) JCRQ1 期刊介紹(非官網(wǎng))

Cell Reports MedicineSCIE

國(guó)際簡(jiǎn)稱：Cell Rep Med 參考譯名：細(xì)胞醫(yī)學(xué)報(bào)道

中科院分區(qū)
1區(qū)
CiteScore分區(qū)
Q1
JCR分區(qū)
Q1

基本信息：: ISSN：2666-3791; E-ISSN：2666-3791; 是否OA：開(kāi)放; 是否預(yù)警：否; TOP期刊：是

出版信息：: 出版地區(qū)：United States; 出版商：Elsevier; 出版語(yǔ)言：English; 出版周期：Monthly; 出版年份：2020; 研究方向：Biochemistry, Genetics and Molecular Biology-Biochemistry, Genetics and Molecular Biology (all)

評(píng)價(jià)信息：: 影響因子：11.7; CiteScore指數(shù)：15; SJR指數(shù)：4.276; SNIP指數(shù)：1.664

發(fā)文數(shù)據(jù)：: Gold OA文章占比：93.57%; 研究類文章占比：95.74%; 年發(fā)文量：305; 自引率：0.0139...; 開(kāi)源占比：0.8876; 出版撤稿占比：; 出版國(guó)人文章占比：0; OA被引用占比：

投稿咨詢加急見(jiàn)刊

英文簡(jiǎn)介期刊介紹 CiteScore數(shù)據(jù) 中科院SCI分區(qū) JCR分區(qū) 發(fā)文數(shù)據(jù) 常見(jiàn)問(wèn)題

英文簡(jiǎn)介Cell Reports Medicine期刊介紹

Cell Reports Medicine is a premium open-access journal from Cell Press publishing cutting-edge research in translational and clinical biomedical sciences that inform and influence human health and medicine.

The content published in Cell Reports Medicine reaches a broad range of scientists and clinicians across the spectrum of medical disciplines, ensuring that your work will be both visible and accessible. The journal publishes original research that ranges from exciting concepts in human biology, health, and disease to all phases of clinical work. We encourage submissions featuring innovative ideas that open up new directions in clinical research and practice, as well as studies that provide critical information that enriches our understanding of current standards of care in diagnosis, treatment, and prognosis. This includes, but is not limited to, translational studies, clinical trials in all areas of medicine including long-term trial follow-ups as well as work in genomics, biomarker discovery, and developments in technology that contribute to diagnostics, treatment, and healthcare. Studies based on vertebrate model organisms also fall within the scope of the journal, provided that the results are directly relevant to human health and disease.

Like our sister journal Cell Reports, we will consider impactful, single-point papers called reports, in addition to longer articles. Large datasets, techniques, and tools for the community can also be considered under the article format. We will also publish reviews covering recent literature in emerging and active fields.

The professional in-house scientific editors at Cell Reports Medicine work closely with authors, reviewers, and the journal's editorial board to ensure exemplary editorial process, fair and robust peer review, and rapid dissemination and communication of your research.

期刊簡(jiǎn)介Cell Reports Medicine期刊介紹

《Cell Reports Medicine》自2020出版以來(lái)，是一本醫(yī)學(xué)優(yōu)秀雜志。致力于發(fā)表原創(chuàng)科學(xué)研究結(jié)果，并為醫(yī)學(xué)各個(gè)領(lǐng)域的原創(chuàng)研究提供一個(gè)展示平臺(tái)，以促進(jìn)醫(yī)學(xué)領(lǐng)域的的進(jìn)步。該刊鼓勵(lì)先進(jìn)的、清晰的闡述，從廣泛的視角提供當(dāng)前感興趣的研究主題的新見(jiàn)解，或?qū)彶槎嗄陙?lái)某個(gè)重要領(lǐng)域的所有重要發(fā)展。該期刊特色在于及時(shí)報(bào)道醫(yī)學(xué)領(lǐng)域的最新進(jìn)展和新發(fā)現(xiàn)新突破等。該刊近一年未被列入預(yù)警期刊名單，目前已被權(quán)威數(shù)據(jù)庫(kù)SCIE收錄，得到了廣泛的認(rèn)可。

該期刊投稿重要關(guān)注點(diǎn)：

預(yù)計(jì)審稿時(shí)間：約Time to desk decision: 6.6 days; Publication time: 3.31 weeks 17 Weeks
國(guó)際TOP期刊
醫(yī)學(xué)
MEDICINE, RESEARCH & EXPERIMENTAL
SCIE
中科院1區(qū)
非預(yù)警

Cite Score數(shù)據(jù)（2024年最新版）Cell Reports Medicine Cite Score數(shù)據(jù)

CiteScore：15
SJR：4.276
SNIP：1.664

學(xué)科類別	分區(qū)	排名	百分位
大類：Medicine 小類：General Medicine	Q1	25 / 636	96%
大類：Medicine 小類：General Biochemistry, Genetics and Molecular Biology	Q1	18 / 221	92%

CiteScore 是由Elsevier(愛(ài)思唯爾)推出的另一種評(píng)價(jià)期刊影響力的文獻(xiàn)計(jì)量指標(biāo)。反映出一家期刊近期發(fā)表論文的年篇均引用次數(shù)。CiteScore以Scopus數(shù)據(jù)庫(kù)中收集的引文為基礎(chǔ)，針對(duì)的是前四年發(fā)表的論文的引文。CiteScore的意義在于，它可以為學(xué)術(shù)界提供一種新的、更全面、更客觀地評(píng)價(jià)期刊影響力的方法，而不僅僅是通過(guò)影響因子(IF)這一單一指標(biāo)來(lái)評(píng)價(jià)。

歷年Cite Score趨勢(shì)圖

中科院SCI分區(qū)Cell Reports Medicine 中科院分區(qū)

中科院 2023年12月升級(jí)版 綜述期刊：否 Top期刊：是

大類學(xué)科	分區(qū)	小類學(xué)科	分區(qū)
醫(yī)學(xué)	1區(qū)	MEDICINE, RESEARCH & EXPERIMENTAL 醫(yī)學(xué)：研究與實(shí)驗(yàn) CELL BIOLOGY 細(xì)胞生物學(xué)	1區(qū) 2區(qū)

中科院分區(qū)表 是以客觀數(shù)據(jù)為基礎(chǔ)，運(yùn)用科學(xué)計(jì)量學(xué)方法對(duì)國(guó)際、國(guó)內(nèi)學(xué)術(shù)期刊依據(jù)影響力進(jìn)行等級(jí)劃分的期刊評(píng)價(jià)標(biāo)準(zhǔn)。它為我國(guó)科研、教育機(jī)構(gòu)的管理人員、科研工作者提供了一份評(píng)價(jià)國(guó)際學(xué)術(shù)期刊影響力的參考數(shù)據(jù)，得到了全國(guó)各地高校、科研機(jī)構(gòu)的廣泛認(rèn)可。

中科院分區(qū)表 將所有期刊按照一定指標(biāo)劃分為1區(qū)、2區(qū)、3區(qū)、4區(qū)四個(gè)層次，類似于“優(yōu)、良、及格”等。最開(kāi)始，這個(gè)分區(qū)只是為了方便圖書(shū)管理及圖書(shū)情報(bào)領(lǐng)域的研究和期刊評(píng)估。之后中科院分區(qū)逐步發(fā)展成為了一種評(píng)價(jià)學(xué)術(shù)期刊質(zhì)量的重要工具。

歷年中科院分區(qū)趨勢(shì)圖

JCR分區(qū)Cell Reports Medicine JCR分區(qū)

2023-2024 年最新版

按JIF指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：CELL BIOLOGY	SCIE	Q1	22 / 205	89.5%
學(xué)科：MEDICINE, RESEARCH & EXPERIMENTAL	SCIE	Q1	10 / 189	95%

按JCI指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：CELL BIOLOGY	SCIE	Q1	14 / 205	93.41%
學(xué)科：MEDICINE, RESEARCH & EXPERIMENTAL	SCIE	Q1	8 / 189	96.03%

JCR分區(qū)的優(yōu)勢(shì)在于它可以幫助讀者對(duì)學(xué)術(shù)文獻(xiàn)質(zhì)量進(jìn)行評(píng)估。不同學(xué)科的文章引用量可能存在較大的差異，此時(shí)單獨(dú)依靠影響因子(IF)評(píng)價(jià)期刊的質(zhì)量可能是存在一定問(wèn)題的。因此，JCR將期刊按照學(xué)科門(mén)類和影響因子分為不同的分區(qū)，這樣讀者可以根據(jù)自己的研究領(lǐng)域和需求選擇合適的期刊。

歷年影響因子趨勢(shì)圖

本刊中國(guó)學(xué)者近年發(fā)表論文

1、Current understanding of the intratumoral microbiome in various tumors
Author: Xue, Chen; Chu, Qingfei; Zheng, Qiuxian; Yuan, Xin; Su, Yuanshuai; Bao, Zhengyi; Lu, Juan; Li, Lanjuan

Journal: CELL REPORTS MEDICINE. 2023; Vol. 4, Issue 1, pp. -. DOI: 10.1016/j.xcrm.2022.100884
2、Inherited mutations in Chinese patients with upper tract urothelial carcinoma
Author: Wu, Junlong; Jin, Shengming; Gu, Chengyuan; Wei, Yu; Zhu, Yao; Necchi, Andrea; Shariat, Shahrokh F.; Pan, Jian; Gan, Hualei; Dai, Bo; Zhang, Hailiang; Shi, Guohai; Zhu, Yu; Shen, Yijun; Zhu, Yiping; Ye, Dingwei

Journal: CELL REPORTS MEDICINE. 2023; Vol. 4, Issue 1, pp. -. DOI: 10.1016/j.xcrm.2022.100883
3、Exosome-based bone-targeting drug delivery alleviates impaired osteoblastic bone formation and bone loss in inflammatory bowel diseases
Author: Guo, Jiawei; Wang, Fuxiao; Hu, Yan; Luo, Ying; Wei, Yan; Xu, Ke; Zhang, Hao; Liu, Han; Bo, Lumin; Lv, Shunli; Sheng, Shihao; Zhuang, Xinchen; Zhang, Tao; Xu, Can; Chen, Xiao; Su, Jiacan

Journal: CELL REPORTS MEDICINE. 2023; Vol. 4, Issue 1, pp. -. DOI: 10.1016/j.xcrm.2022.100881
4、Single-cell sequencing identifies differentiation-related markers for molecular classification and recurrence prediction of PitNET
Author: Zhang, Qilin; Yao, Boyuan; Long, Xin; Chen, Zhengyuan; He, Min; Wu, Yue; Qiao, Nidan; Ma, Zengyi; Ye, Zhao; Zhang, Yichao; Yao, Shun; Wang, Ye; Cheng, Haixia; Chen, Hong; Ye, Hongying; Wang, Yongfei; Li, Yimin; Chen, Jianhua; Zhang, Zhaoyun; Guo, Fan; Zhao, Yao

Journal: CELL REPORTS MEDICINE. 2023; Vol. 4, Issue 2, pp. -. DOI: 10.1016/j.xcrm.2023.100934
5、Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study
Author: Wang, Han-Min; Zhang, Chan-Yuan; Peng, Kai-Cheng; Chen, Ze-Xin; Su, Jun-Wei; Li, Yu-Fa; Li, Wen-Feng; Gao, Qing-Yun; Zhang, Shi-Ling; Chen, Yu-Qing; Zhou, Qing; Xu, Cong; Xu, Chong-Rui; Wang, Zhen; Su, Jian; Yan, Hong-Hong; Zhang, Xu-Chao; Chen, Hua-Jun; Wu, Yi-Long; Yang, Jin-Ji

Journal: CELL REPORTS MEDICINE. 2023; Vol. 4, Issue 2, pp. -. DOI: 10.1016/j.xcrm.2022.100911
6、Diagnostic performance and prognostic value of circulating tumor DNA methylation marker in extranodal natural killer/T cell lymphoma
Author: Tian, Xiao-Peng; Zhang, Yu-Chen; Lin, Ning-Jing; Wang, Liang; Li, Zhi-Hua; Guo, Han-Guo; Ma, Shu-Yun; An, Ming-Jie; Yang, Jing; Hong, Yu-Heng; Wang, Xian-Huo; Zhou, Hui; Li, Ya-Jun; Rao, Hui-Lan; Li, Mei; Hu, Shao-Xuan; Lin, Tong-Yu; Li, Zhi-Ming; Huang, He; Liang, Yang; Xia, Zhong-Jun; Lv, Yue; Liu, Yu-Ying; Duan, Zhao-Hui; Chen, Qing-Yu; Wang, Jin-Ni; Cai, Jun; Xie, Ying; Ong, Choon-Kiat; Liu, Fang; Liu, Yan-yan; Yan, Zheng; Huang, Liang; Tao, Rong; Li, Wen-Yu; Huang, Hui-Qiang; Cai, Qing-Qing

Journal: CELL REPORTS MEDICINE. 2023; Vol. 4, Issue 2, pp. -. DOI: 10.1016/j.xcrm.2022.100859
7、Multiplex immune profiling reveals the role of serum immune proteomics in predicting response to preoperative chemotherapy of gastric cancer
Author: Tang, Zhaoqing; Gu, Yuan; Shi, Zhongyi; Min, Lingqiang; Zhang, Ziwei; Zhou, Peng; Luo, Rongkui; Wang, Yan; Cui, Yuehong; Sun, Yihong; Wang, Xuefei

Journal: CELL REPORTS MEDICINE. 2023; Vol. 4, Issue 2, pp. -. DOI: 10.1016/j.xcrm.2023.100931
8、DeepFundus: A flow-cytometry-like image quality classifier for boosting the whole life cycle of medical artificial intelligence
Author: Liu, Lixue; Wu, Xiaohang; Lin, Duoru; Zhao, Lanqin; Li, Mingyuan; Yun, Dongyuan; Lin, Zhenzhe; Pang, Jianyu; Li, Longhui; Wu, Yuxuan; Lai, Weiyi; Xiao, Wei; Shang, Yuanjun; Feng, Weibo; Tan, Xiao; Li, Qiang; Liu, Shenzhen; Lin, Xinxin; Sun, Jiaxin; Zhao, Yiqi; Yang, Ximei; Ye, Qinying; Zhong, Yuesi; Huang, Xi; He, Yuan; Fu, Ziwei; Xiang, Yi; Zhang, Li; Zhao, Mingwei; Qu, Jinfeng; Xu, Fan; Lu, Peng; Li, Jianqiao; Xu, Fabao; Wei, Wenbin; Dong, Li; Dai, Guangzheng; He, Xingru; Yan, Wentao; Zhu, Qiaolin; Lu, Linna; Zhang, Jiaying; Zhou, Wei; Meng, Xiangda; Li, Shiying; Shen, Mei; Jiang, Qin; Chen, Nan; Zhou, Xingtao; Li, Meiyan; Wang, Yan; Zou, Haohan; Zhong, Hua; Yang, Wenyan; Shou, Wulin; Zhong, Xingwu; Yang, Zhenduo; Ding, Lin; Hu, Yongcheng; Tan, Gang; He, Wanji; Zhao, Xin; Chen, Yuzhong; Liu, Yizhi; Lin, Haotian

Journal: CELL REPORTS MEDICINE. 2023; Vol. 4, Issue 2, pp. -. DOI: 10.1016/j.xcrm.2022.100912